Outcomes and Safety of Blenderized Tube Feedings in Pediatric Patients: A Single Center's Experience
Outcomes and Safety of Blenderized Tube Feedings in Pediatric Patients: A Single Center's Experience
复制标题
DOI：
10.1097/mpg.0000000000002853
复制
发表时间：
2020-10-01
影响因子：
2.9
通讯作者：
Weidner, Melissa
中科院分区：
文献类型：
--
作者：
Kernizan, Daphney;Mintz, Daria;Weidner, Melissa
简介：最近，家庭和医疗保健提供者对使用混合管饲（BTF）产生了极大的兴趣。虽然许多机构提供这种营养的选择，文献记录的结果和安全性是lacked.Methods：一个回顾性的图表审查，在罗格斯-罗伯特伍德约翰逊大学医院2013年1月至2017年4月之间接受BTF的儿科患者进行。收集BTF前后的人口学资料和饮食信息。记录饮食开始的原因、症状和人体测量学。不良事件和结果进行了评估，通过医生的文件和相关的药物changes.Results：35例（24名男孩）接受BTF。开始BTF治疗时的年龄范围为1 - 19岁（平均8.3 ± 5.8 [SD]岁）。随访时间范围为1至45个月（平均15 +/- 12.2个月）。开始BTF的最常见原因是胃食管反流病（GERD）（N = 32）。几乎所有患者在开始BTF治疗前均接受GERD、便秘或胃肠动力障碍药物治疗（N = 33）。大多数患者的相关症状改善（N = 20）; 33例接受胃肠道药物治疗的患者中有13例能够撤药或停药。BTF开始前后BMI z评分无差异（P = 0.558）。没有严重危及生命的不良事件被发现。结论：我们的数据表明，BTF是一种安全的饮食干预，可能会改善儿科患者的胃肠道症状。需要进一步的前瞻性研究来比较BTF和商业配方在儿科患者中的安全性和有效性。
Introduction: Recently, significant interest from families and healthcare providers has arisen to use blenderized tube feedings (BTF). Although many institutions are providing this nutritional option, literature documenting outcomes and safety is lacking.Methods: A retrospective chart review was performed on pediatric patients receiving BTF at Rutgers-Robert Wood Johnson University Hospital between January 2013 and April 2017. Demographic data and dietary information before and after BTF were collected. Reasons for diet initiation, symptoms, and anthropometrics were recorded. Adverse events and outcomes were assessed through physician documentation and relevant medication changes.Results: Thirty-five patients (24 boys) received BTF. Age at initiation of BTF ranged from 1 to 19 years (mean 8.3 +/- 5.8 [SD] years). Length of follow-up ranged from 1 to 45 months (mean 15 +/- 12.2 months). The most common reason for starting BTF was gastroesophageal reflux disease(GERD) (N = 32). Almost all patients were on medications for GERD, constipation, or gastrointestinal dysmotility before starting BTF (N = 33). Majority of patients had improvement in relevant symptoms (N = 20); 13 of 33 patients on gastrointestinal medications were able to wean or stop medication(s). BMI z scores did not differ before and after BTF initiation (P = 0.558). No serious life-threatening adverse events were found.Conclusions: Our data suggest that BTF is a safe dietary intervention that may improve gastrointestinal symptoms in pediatric patients. Further prospective studies are needed to compare safety and efficacy of BTF and commercial formulas in pediatric patients.